Jade Biosciences, Inc. (JBIO) – What Are Analysts Thinking About This Stock?

Jade Biosciences, Inc. (NASDAQ:JBIO) has been given a consensus recommendation of “Moderate Buy” by the ten research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $51.75.

JBIO has been the subject of a number of analyst reports. BTIG Research lifted their price target on Jade Biosciences from $74.00 to $77.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Wedbush reissued an “outperform” rating and issued a $47.00 price objective on shares of Jade Biosciences in a research note on Thursday, October 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Jade Biosciences in a research note on Friday, September 11th. Wall Street Zen lowered Jade Biosciences from a “sell” rating to a “strong sell” rating in a report on Saturday, September 12th. Finally, HC Wainwright restated a “buy” rating and issued a $55.00 target price on shares of Jade Biosciences in a report on Thursday, October 1st.

Jade Biosciences Price Performance

NASDAQ:JBIO opened at $13.83 on Tuesday. The firm has a 50-day moving average of $17.95 and a 200-day moving average of $19.74. The company has a market cap of $879.59 million, a PE ratio of -7.20 and a beta of 1.64. Jade Biosciences has a one year low of $8.36 and a one year high of $28.00.

Jade Biosciences (NASDAQ:JBIO) last posted its earnings results on Monday, August 10th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). On average, equities research analysts expect that Jade Biosciences will post -2.89 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Jade Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Engineers Gate Manager LP bought a new position in Jade Biosciences during the 2nd quarter valued at $503,000. Y Intercept Hong Kong Ltd purchased a new position in Jade Biosciences during the 1st quarter worth $353,000. Quantinno Capital Management LP boosted its holdings in Jade Biosciences by 3.6% during the 1st quarter. Quantinno Capital Management LP now owns 30,551 shares of the company’s stock worth $429,000 after acquiring an additional 1,059 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Jade Biosciences by 2.9% in the 1st quarter. Bank of America Corp DE now owns 38,598 shares of the company’s stock worth $542,000 after acquiring an additional 1,086 shares in the last quarter. Finally, Maven Securities LTD bought a new stake in shares of Jade Biosciences in the 2nd quarter worth $1,111,000.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. The company’s research and development efforts are directed toward antibody-based medicines designed to address significant unmet needs in immune-mediated conditions.

Jade’s pipeline includes investigational therapeutic programs intended to modulate biological pathways involved in inflammation and immune-system activity. As a development-stage company, its products remain subject to clinical testing and regulatory review, and there is no assurance that any candidate will receive approval or reach the commercial market.

The company is headquartered in the United States and is developing its portfolio for potential use in global markets.